NYOXE
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Nyota Minerals Limited - Entitlement To Shares In Kefi Minerals PLC
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in NYOXE
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in NYOXE
N/A
NYOXE investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in NYOXE also invest in...
Want more shares? Try these...
NYR
Nyrada, Inc. is a pre-clinical stage, drug discovery, and development company, which engages in the business of specializing in novel small molecule drugs to treat cardiovascular and neurological diseases. The company is headquartered in Gordon, New South Wales. The company went IPO on 2020-01-16. The Company’s lead candidate, NYR-BI03, has shown efficacy in both neuroprotection and cardioprotection. The NYR-BI03 has potential to fill a significant treatment gap targeting ischemia-reperfusion injury. NYR-BI03 additionally has the potential to provide dual protection for both the heart and brain from ischemia-reperfusion damage, helping prevent heart failure and neurological damage. Its Neuroprotection Program is a neuroprotectant drug to reduce the impact of long-term disability in patients who suffer a traumatic brain injury or ischaemic stroke. Its Cardioprotection Program is a cardioprotectant drug to reduce the damage to the heart following myocardial infarction (heart attack).
🙌 Performance (5Yr p.a)
-7.88%
📊 Share price
$0.10 AUD
📦 LOGISTICS
